NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results